Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

USA - NASDAQ:AXSM - US05464T1043 - Common Stock

129.72 USD
-1.67 (-1.27%)
Last: 10/22/2025, 8:16:55 PM
129.72 USD
0 (0%)
After Hours: 10/22/2025, 8:16:55 PM
Fundamental Rating

2

Taking everything into account, AXSM scores 2 out of 10 in our fundamental rating. AXSM was compared to 191 industry peers in the Pharmaceuticals industry. AXSM has a bad profitability rating. Also its financial health evaluation is rather negative. AXSM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AXSM has reported negative net income.
In the past year AXSM has reported a negative cash flow from operations.
AXSM had negative earnings in each of the past 5 years.
AXSM had a negative operating cash flow in each of the past 5 years.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -38.59%, AXSM perfoms like the industry average, outperforming 46.07% of the companies in the same industry.
AXSM's Return On Equity of -337.87% is on the low side compared to the rest of the industry. AXSM is outperformed by 74.87% of its industry peers.
Industry RankSector Rank
ROA -38.59%
ROE -337.87%
ROIC N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

AXSM has a Gross Margin of 91.48%. This is amongst the best in the industry. AXSM outperforms 94.76% of its industry peers.
The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AXSM has been increased compared to 5 years ago.
AXSM has a worse debt/assets ratio than last year.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 4.20 indicates that AXSM is not in any danger for bankruptcy at the moment.
The Altman-Z score of AXSM (4.20) is better than 77.49% of its industry peers.
AXSM has a Debt/Equity ratio of 2.62. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.62, AXSM is not doing good in the industry: 80.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.62
Debt/FCF N/A
Altman-Z 4.2
ROIC/WACCN/A
WACC8.81%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.57 indicates that AXSM should not have too much problems paying its short term obligations.
AXSM's Current ratio of 1.57 is on the low side compared to the rest of the industry. AXSM is outperformed by 67.54% of its industry peers.
AXSM has a Quick Ratio of 1.51. This is a normal value and indicates that AXSM is financially healthy and should not expect problems in meeting its short term obligations.
AXSM's Quick ratio of 1.51 is on the low side compared to the rest of the industry. AXSM is outperformed by 60.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.51
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

AXSM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.12%, which is quite impressive.
AXSM shows a strong growth in Revenue. In the last year, the Revenue has grown by 69.83%.
EPS 1Y (TTM)22.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.92%
Revenue 1Y (TTM)69.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%72.13%

3.2 Future

AXSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.95% yearly.
The Revenue is expected to grow by 46.50% on average over the next years. This is a very strong growth
EPS Next Y37.32%
EPS Next 2Y46.13%
EPS Next 3Y49.62%
EPS Next 5Y39.95%
Revenue Next Year60.83%
Revenue Next 2Y58.25%
Revenue Next 3Y56.25%
Revenue Next 5Y46.5%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
AXSM is valuated quite expensively with a Price/Forward Earnings ratio of 160.11.
AXSM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AXSM is cheaper than 67.54% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AXSM to the average of the S&P500 Index (23.09), we can say AXSM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 160.11
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as AXSM's earnings are expected to grow with 49.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.13%
EPS Next 3Y49.62%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (10/22/2025, 8:16:55 PM)

After market: 129.72 0 (0%)

129.72

-1.67 (-1.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners76.11%
Inst Owner Change0.24%
Ins Owners1.15%
Ins Owner Change-1.66%
Market Cap6.47B
Revenue(TTM)495.03M
Net Income(TTM)-246900000
Analysts86.15
Price Target179.07 (38.04%)
Short Float %8.35%
Short Ratio5.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.55%
Min EPS beat(2)9.8%
Max EPS beat(2)13.31%
EPS beat(4)3
Avg EPS beat(4)-4.68%
Min EPS beat(4)-48.67%
Max EPS beat(4)13.31%
EPS beat(8)3
Avg EPS beat(8)-17.56%
EPS beat(12)5
Avg EPS beat(12)-8.93%
EPS beat(16)8
Avg EPS beat(16)-4.77%
Revenue beat(2)1
Avg Revenue beat(2)2.68%
Min Revenue beat(2)-0.65%
Max Revenue beat(2)6.01%
Revenue beat(4)2
Avg Revenue beat(4)2.03%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)6.01%
Revenue beat(8)5
Avg Revenue beat(8)1.73%
Revenue beat(12)8
Avg Revenue beat(12)24.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.03%
EPS NQ rev (1m)0.89%
EPS NQ rev (3m)-12.52%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-3.07%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 160.11
P/S 13.08
P/FCF N/A
P/OCF N/A
P/B 88.58
P/tB 374.16
EV/EBITDA N/A
EPS(TTM)-5.07
EYN/A
EPS(NY)0.81
Fwd EY0.62%
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS9.92
BVpS1.46
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.59%
ROE -337.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.48%
FCFM N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 2.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.53%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.51
Altman-Z 4.2
F-Score5
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.92%
EPS Next Y37.32%
EPS Next 2Y46.13%
EPS Next 3Y49.62%
EPS Next 5Y39.95%
Revenue 1Y (TTM)69.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%72.13%
Revenue Next Year60.83%
Revenue Next 2Y58.25%
Revenue Next 3Y56.25%
Revenue Next 5Y46.5%
EBIT growth 1Y24.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3Y55.68%
EBIT Next 5Y45%
FCF growth 1Y-8.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.2%
OCF growth 3YN/A
OCF growth 5YN/A